Who are Ascelia's investors?

Ascelia's investors include Sunstone Capital.

Where is Ascelia headquartered?

Ascelia is headquartered in Malmö, SE.

Ascelia

Malmö, SE · Founded 2000 · 14 employees on LinkedIn · 1 known investors

Find your way into Ascelia

Each arrow is one introduction. Sign up to fill in the first one.

614 people can intro you to Magnus

Ask Line Jacobsen to introduce you to Magnus Corfitzen

You →Line · together at Vaekstfonden →Magnus

547 people can intro you to Andreas

Ask Jamie Chen to introduce you to Andreas Norlin

You →Jamie · together at ApoGlyx →Andreas

189 people can intro you to Jennie

Ask Sam Okafor to introduce you to Jennie Wilborgsson

You →Sam · together at Ferring Pharmaceuticals →Jennie

Your email: who you already know at Ascelia, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Ascelia team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Ascelia Pharma is a biotech company developing and commercializing drugs for rare, orphan oncology-related conditions with unmet medical needs. Its clinical-stage pipeline includes Orviglance, an oral MRI contrast agent for detecting liver lesions, and Oncoral, an oral chemotherapy tablet for gastric cancer.

Biotech Healthtech Medical Devices

Founders & leadership

Magnus Corfitzen Chief Executive OfficerMagnus Corfitzen has more than 20 years of experience in life sciences, having held operational and investment roles at biotech and medtech companies, served on the boards of 12 life science firms, and been involved in financing and business development transactions. He is Chief Executive Officer of Ascelia Pharma, a biotech company developing oral drugs for rare oncology conditions.

Andreas Norlin Chief Scientific OfficerAndreas Norlin brings more than 20 years of experience in drug development across academia, biotech, and pharmaceutical companies, with expertise spanning preclinical and clinical development, regulatory affairs, and R&D management. His background encompasses project leadership, portfolio management, and cross-functional collaboration in the fields of diabetes, inflammatory disease, and drug delivery technologies.

Jennie Wilborgsson Chief Operating OfficerJennie Wilborgsson has over 15 years of experience in clinical drug development across Phase I–IV trials, with background in both sponsor and contract research organization roles, and has led clinical development teams managing multiple pipeline projects.

Anton HanssonChief Financial Officer

Investors · 1

Sunstone Capitallisted by Sunstone CapitalFrederiksberg

How we know: Sunstone Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountDirected Share IssueApr 2026
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does Ascelia do?: Ascelia Pharma is a biotech company developing and commercializing drugs for rare, orphan oncology-related conditions with unmet medical needs. Its clinical-stage pipeline includes Orviglance, an oral MRI contrast agent for detecting liver lesions, and Oncoral, an oral chemotherapy tablet for gastric cancer.
Who are Ascelia's investors?: Ascelia's investors include Sunstone Capital.
Where is Ascelia headquartered?: Ascelia is headquartered in Malmö, SE.